Can a targeted antibody boost kidney remission in lupus?

NCT ID NCT07767188

NEW Not yet recruiting Disease control Sponsor: Zhao Minghui Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This phase 3 trial is testing whether adding the drug obinutuzumab to the standard treatment (mycophenolate mofetil and corticosteroids) can improve outcomes for people with active lupus nephritis, a serious kidney complication of lupus. The study will enroll 70 adults aged 18-65 with confirmed active lupus nephritis. Participants will receive obinutuzumab infusions at specified intervals over a year, alongside standard therapy. The main goal is to see how many achieve a complete renal response by week 76, meaning their kidney function stabilizes and protein in the urine drops to a healthy level.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: obinutuzumab
What this could lead to: If successful, this could lead to a new first-line treatment option for lupus nephritis that improves kidney outcomes.
What could go wrong: This is a single-arm trial without a placebo control, so results may be influenced by the standard therapy alone. Obinutuzumab can have side effects, including infusion reactions and increased infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS NEPHRITIS

Contacts and locations

Locations

Fujian Medical University Union Hospital

Fuzhou, Fujian, China
Guangdong Provincial People's Hospital

Guangzhou, Guangdong, China
Jiangsu Province Hospital

Nanjing, Jiangsu, China
Peking University First Hospital

Beijing, China
Shengjing Hospital affiliated to China Medical University

Shenyang, Liaoning, China
The Affiliated Hospital of Southwest Medical University

Luzhou, Sichuan, China
The Affiliated Hospital of Xuzhou Medical University

Xuzhou, Jiangsu, China
The First Affiliated Hospital of Harbin Medical University

Harbin, Heilongjiang, China
The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China
The First Affiliated Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, China
The Second Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, China
Tianjin Medical University General Hospita

Tianjin, Tianjin Municipality, China
Yantai Yuhuangding Hospital

Yantai, Shandong, China
Zhujiang Hospital of Southern Medical University

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.